BioCardia, which is developing regenerative medicine for heart failure based a patient's own bone marrow, postponed its IPO on Tuesday.
The company had intended to raise $50 million by offering 3.85 million shares at a proposed price range of $12 to $14.
The San Carlos, CA-based company was founded in 2002 and had planned to list on the Nasdaq under the symbol BCDA. Cantor Fitzgerald, Roth Capital and Maxim Group LLC were set to be the joint bookrunners on the deal.
IPO Pro - "The Ultimate Resource for IPOs"
Don't risk buying another IPO without IPO Pro.
Get your FREE TRIAL now.
